Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Reovirus
Data from C.L. White and colleagues advance knowledge in reovirus
August 26th, 2008
"There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer virotherapy. However, there is a dearth of clinical data on the immune response to viral agents in patients," scientists in London, the United Kingdom report. "During a recently completed phase I trial of intravenous reovirus type 3 Dearing (RT3D), heavily pretreated patients with advanced cancers received RT3D at doses escalating from 1 x10(8) tissue culture infectious dose-50 (TCID50) on day 1 to 3 x 10(10) TCID50 on 5 consecutive days of a 4 weekly cycle. A detailed analysis of the immune effects was conducted by...
Source: Cancer Weekly (2008-08-26)
|
